Targovax releases update for mesothelioma trial combining ONCOS-102 and chemotherapy
· Progression free survival at the 9-month follow-up is tracking in line with previously published data · Immune activation is further validated in the ONCOS-102 treated group · First line mesothelioma remains the focus for next phase of development Oslo, Norway, 4 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today releases an update from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma. The trial is